China Clinical Trial Supplies Market Size & Outlook
China clinical trial supplies market, 2018-2030 (US$M)
Related Markets
China clinical trial supplies market highlights
- The China clinical trial supplies market generated a revenue of USD 151.4 million in 2023 and is expected to reach USD 250.5 million by 2030.
- The China market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, phase iii was the largest revenue generating phase in 2023.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Clinical trial supplies market data book summary
| Market revenue in 2023 | USD 151.4 million |
| Market revenue in 2030 | USD 250.5 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III |
| Key market players worldwide | Almac Group, Catalent Inc, Waldencast PLC Class A, PCI Technology, Sharp Corp, Thermo Fisher Scientific Inc, PAREXEL, Marken, KLIFO, BioCair |
Other key industry trends
- In terms of revenue, China accounted for 5.9% of the global clinical trial supplies market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China clinical trial supplies market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 149.7 million by 2030.
Phase iii was the largest segment with a revenue share of 53.57% in 2023. Horizon Databook has segmented the China clinical trial supplies market based on phase i, phase ii, phase iii covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the lucrative markets for clinical trial supplies players owing to its diverse pool of patients and growing pharmaceutical market. Logistics and supply chain is a major challenge in the country, which is discouraging major biopharmaceutical companies from conducting trials in China.
The country accounts for 34.83% of global clinical trials conducted as of 2020 and has exhibited lucrative growth in the past 3 years. The trend is driving the entry of major players such as Catalent Pharma Solutions in China, which is expected to contribute to the growth of clinical supplies market in the country.
In 2013, Catalent Pharma Solutions, a global clinical trial supplies company, started its clinical supply chain facility in Shanghai to expand its presence in Asia, Australia, and New Zealand. Shanghai is an international depot with access to major developing and international centers.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Trial Supplies Market Scope
Clinical Trial Supplies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China clinical trial supplies market size, by phase, 2018-2030 (US$M)
China Clinical Trial Supplies Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
